Pelthos Therapeutics Inc. (PTHS) Form 8-K — May 14, 2026
Pelthos Therapeutics Inc. reported a 17% quarter-over-quarter increase in net product revenue for ZELSUVMI, from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026. This growth is attributed to the expansion of the sales force and focused commercial execution. The company secured a $50.0 million senior secured term loan facility from Horizon Technology Finance, of which $30.0 million was drawn at close.
Key figures
- Eps Beat
- 0
- Revenue
- 10665
- Total Debt
- 110276
- Debt Amount
- 50000
- Revenue Yoy
- 0
- Total Assets
- 145378
- Cash Position
- 31976
- Deal Value Usd
- 50000
- Interest Rate
- 0
- Gross Proceeds
- 30000
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 8900000
- Horizon Loan Drawn
- 30000
- Horizon Loan Amount
- 50000
- Commercial Launch Date
- July 2025
- Units Dispensed Q12026
- 7884
- Units Dispensed Q42025
- 6312
- Unique Prescribers Q12026
- 3228
- Unique Prescribers Q42025
- 2377
- Total Prescribed Units Since Launch
- 20000
Price after filing
1 day: 0.0%7 days: -2.1%30 days: +3.7%
Close on the filing date to close N calendar days later (from $27.69). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.